Chat with us, powered by LiveChat

Neuromodulation Market (Technology - Deep Brain Stimulation, Spinal Cord Stimulation, Gastric Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, and Others; Application - Chronic Pain, Parkinson’s Disease, Dystonia, Essential Tremor, Refractory Epilepsy, Treatment Resistant Depression (TRD), Urinary Fecal Incontinence, and Other Applications): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Neuromodulation Market (Technology - Deep Brain Stimulation, Spinal Cord Stimulation, Gastric Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, and Others; Application - Chronic Pain, Parkinson’s Disease, Dystonia, Essential Tremor, Refractory Epilepsy, Treatment Resistant Depression (TRD), Urinary Fecal Incontinence, and Other Applications): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR082 Category: Healthcare & Medical Devices Published: December, 2023

A recent report published by Infinium Global Research on neuromodulation market provides in-depth analysis of segments and sub-segments in the global as well as regional neuromodulation market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional neuromodulation market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global neuromodulation market.

Market Insight:

The global neuromodulation market was valued at USD 3.51 Billion in 2022 and is expected to reach USD 7.27 Billion in 2030, with a CAGR of 9.59% during the forecast period 2023-2030.

The neuromodulation market is a dynamic and rapidly expanding segment of the healthcare industry that specializes in the creation and deployment of advanced medical devices aimed at regulating and enhancing the performance of the nervous system. These innovative devices are precisely engineered to mitigate symptoms and enhance the quality of life for individuals grappling with a spectrum of neurological disorders, chronic pain, and related conditions. This market encompasses a diverse array of cutting-edge technologies, including spinal cord stimulators, deep brain stimulators, and various implantable devices that employ electrical or chemical stimulation to influence nerve activity in a precise and therapeutic manner. The escalating prevalence of neurological disorders and chronic pain conditions on a global scale is driving robust demand for neuromodulation solutions. This burgeoning market's growth is further propelled by ongoing technological advancements, heightened awareness of non-pharmacological treatment options, and the mounting preference for minimally invasive interventions.

The neuromodulation market is driven by ongoing advancements in technology. Innovations such as miniaturization, improved battery life, enhanced stimulation parameters, and the development of advanced software and hardware components are driving the market forward. These technological improvements contribute to more effective and minimally invasive neuromodulation devices, attracting both patients and healthcare providers seeking more efficient, precise, and patient-friendly solutions. Businesses that invest in and leverage these advancements can gain a competitive edge by offering cutting-edge products that provide better clinical outcomes, improved patient experiences, and cost-effective solutions. Moreover, the expanding applications of neuromodulation across various medical conditions contribute significantly to the market's growth. As research continues to demonstrate the clinical efficacy of neuromodulation in treating conditions such as chronic pain, neurological disorders, movement disorders, psychiatric illnesses, and other emerging applications, the market experiences increased acceptance and adoption. Businesses focusing on diversifying their product portfolios to address these multiple clinical applications stand to benefit from the growing demand. However, regulatory hurdles encompass a series of stringent standards, extensive testing requirements, and the need for approvals from various regulatory bodies, such as the FDA in the United States or the CE marking in Europe. These regulations significantly impact the development, approval, and commercialization of neuromodulation devices. Furthermore, expanding applications of non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS) presents a significant opportunity for the market.

North America is expected to hold the most prominent market share in the upcoming forecast period. The dominance of North America in the neuromodulation market can be largely attributed to several key factors. The increase in the aging population in this region has significantly fueled the demand for neurostimulation and related technologies. Moreover, the presence of a robust healthcare infrastructure and a plethora of established key players within the market contributes to the region's substantial market share. These factors combined create a conducive environment for the adoption and growth of neuromodulation devices, ensuring a stronghold for these technologies in the North American market. On the other hand, the Asia-Pacific region emerges as the fastest-growing market within the forecasted period owing to a distinct set of factors. The escalating demand for high-quality, standardized medical facilities in this region, coupled with an increasing ability of individuals to spend on healthcare, contributes to the rapid growth of the neuromodulation market. Additionally, proactive government initiatives aimed at enhancing healthcare services for their citizens have played a pivotal role in driving the growth of this market segment in the Asia-Pacific region.

Report Scope of the Neuromodulation Market:

Report Coverage Details
Market Size in 2022 USD 3.51 Billion
Market Size by 2030 USD 7.27 Billion
Growth Rate from 2023 to 2030 CAGR of 9.59%
Largest Market North America
No. of Pages 180
Market Drivers
  • The neuromodulation market is driven by ongoing advancements in technology.

  • The expanding applications of neuromodulation across various medical conditions contribute significantly to the market's growth.

Market Segmentation By Technology, and By Application
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global neuromodulation market covers segments such as technology, and application. On the basis of technology, the sub-markets include deep brain stimulation, spinal cord stimulation, gastric stimulation, sacral nerve stimulation, vagus nerve stimulation, and others. On the basis of application, the sub-markets include chronic pain, parkinson’s disease, dystonia, essential tremor, refractory epilepsy, treatment resistant depression (trd), urinary fecal incontinence, and other applications.

Companies Profiled:

The report provides profiles of the companies in the market such as Medtronic Plc, Boston Scientific Corporation, Abbott., Cyberonics, Inc., Cochlear Ltd., Advanced Bionics AG and affiliates, Sonova Holding AG, Nevro Corporation, Neuronetics, and Integer Holdings Corporation.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the neuromodulation market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global neuromodulation market was valued at USD 3.51 Billion in 2022.
It is likely to grow at a CAGR of 9.59% during the forecast period 2023-2030.
The global neuromodulation market is estimated to reach USD 7.27 Billion by the end of 2030.
North America is anticipated to exhibit high demand for neuromodulation market during the forecast period.
Medtronic Plc, Boston Scientific Corporation, Abbott., Cyberonics, Inc., Cochlear Ltd., Advanced Bionics AG and affiliates, Sonova Holding AG, Nevro Corporation, Neuronetics, and Integer Holdings Corporation.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.